🔥

Tirzepatide

Mounjaro · Zepbound

High Evidence📈 TrendingFat Loss & Metabolic

A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.

Half-Life

~5 days

4813.5 Da

Amino Acids

N/A

Evidence

High Evidence

Add to Protocol

Regulatory Status

FDA-approved (Mounjaro: T2D, Zepbound: obesity). Major commercial success.

How it works: Add BAC water to your vial → calculator finds concentration → divides your dose by concentration → shows units to draw on a standard 100-unit insulin syringe. Values are pre-filled from research reference defaults — adjust to match your actual vial.

Vial Size (mg)

BAC Water (mL)

Dose (mcg)

fill level

Draw

—

units on a 100-unit syringe

Conc.

—

mcg/mL

Vol/dose

—

Doses/vial

inj.

Titration Schedule

Weeks 1–42.5 mgStart here

Weeks 5–85 mg

Weeks 9–127.5 mg

Weeks 13–1610 mg

Weeks 17–2012.5 mg

Weeks 21+15 mg

Research reference values only. Confirm all parameters with current literature and your clinician.

Looking for multi-compound protocols?

Browse educational protocol discussions that include Tirzepatide.

Protocol Library

Related Compounds

Semaglutide

A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.

Retatrutide

A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.

Liraglutide

A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.

Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.